Impact of Posttreatment SPECT/CT on Patient Management During ¹⁷⁷Lu-PSMA-617 Radiopharmaceutical Therapy.

Abstract

¹⁷⁷Lu can be imaged after administration using SPECT/CT. Most work to date has focused on using posttreatment imaging to measure normal organ and tumor dose. We aimed to assess the impact of posttreatment SPECT/CT on the management of patients undergoing ¹⁷⁷Lu-prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy (RPT). <b>Methods:</b> In this retrospective study, 122 patients underwent PSMA RPT with subsequent SPECT/CT 24 h after treatment. We determined a qualitative response at each cycle and reviewed patient charts to assess the impact that posttreatment SPECT/CT had on patient management. Changes in patient management were classified as changes on the basis of progression and response, and specific cycles when they occurred were noted. Miscellaneous changes in patient management were also evaluated. <b>Results:</b> Among the 122 consecutive patients examined, 42%-56% exhibited stable disease, whereas 19%-39% of patients exhibited response on visual assessment across treatment cycles. In total, 49% (<i>n</i> = 60) of patients experienced changes in management, of which 57% (<i>n</i> = 34) were due to progression, 40% (<i>n</i> = 24) were due to response, and 3% (<i>n</i> = 2) were due to miscellaneous changes. Changes due to disease progression were observed mostly after cycles 2 and 4. Changes due to response to RPT occurred mostly after cycles 3 and 4. <b>Conclusion:</b> At our center, 49% of patients experienced changes in management based on posttreatment SPECT/CT, and most of these changes occurred at cycles 2 and 4. Integrating posttreatment SPECT/CT into routine PSMA RPT protocols can aid in patient management.